Recap - Great news for longtime PropThink readers on Monday morning – BioDelivery Sciences (BDSI) announced positive results from the second of two phase 3 studies testing BEMA-Buprenorphine in chronic pain … Continue Reading
Read nowInsights - Since Mr. Deryugin suggested in December that BioDelivery Sciences (BDSI) would be delivering profits in 2014, this pick is up 175%.
Read nowResearch - Orexigen Therapeutics (OREX) broke above $7 in the Tuesday trading session, a day before the FDA issues a decision on the New Drug Application for NB32 (Contrave) as … Continue Reading
PremiumRecap - First, we’re hosting a networking event for healthcare investors, traders, and analysts on June 17th – details and RSVP here. It’s all about dialog, an investor’s best friend when you’ve … Continue Reading
Read nowRecap - These trades aren’t over yet, and you can catch up on the fundamental theses at PropThink.com. Below, our weekly recap. Shares of Biodelivery Sciences (BDSI) came close to … Continue Reading
Read nowRecap - Incyte (INCY) has been one of PropThink’s most profitable recommendations in the last year. The stock is up nearly 190% since we first began covering the name in July of 2013. This … Continue Reading
Read nowResearch - BioDelivery Sciences (BDSI) and partner Endo Health Solutions (ENDP) announced on the 23rd that the second of three phase 3 trials testing one of its lead drug candidates, BEMA buprenorphine, … Continue Reading
Read now
